Vioxx: an unequal partnership between safety and efficacy.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D012449:Safety; D013450:Sulfones; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib